Evidence map›Paper›PMID 26393553›Full record

ArticleMolecules (Basel, Switzerland)2015

Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists.

Donatella Callegari, Daniele Pala, Laura Scalvini, Massimiliano Tognolini, Matteo Incerti, Silvia Rivara, Marco Mor, Alessio Lodola

Open access · goldAbstract readComparative Study
In one paragraph

Article in Molecules (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Donatella CallegariDipartimento di Farmacia, Università degli Studi di Parma, Parma 43124, Italy. donatella.callegari@studenti.unipr.it.
Daniele PalaDipartimento di Farmacia, Università degli Studi di Parma, Parma 43124, Italy. daniele.pala@nemo.unipr.it.
Laura ScalviniDipartimento di Farmacia, Università degli Studi di Parma, Parma 43124, Italy. laura.scalvini@studenti.unipr.it.
Massimiliano TognoliniDipartimento di Farmacia, Università degli Studi di Parma, Parma 43124, Italy. massimiliano.tognolini@unipr.it.
Matteo IncertiDipartimento di Farmacia, Università degli Studi di Parma, Parma 43124, Italy. matteo.incerti@unipr.it.
Silvia RivaraDipartimento di Farmacia, Università degli Studi di Parma, Parma 43124, Italy. silvia.rivara@unipr.it.
Marco MorDipartimento di Farmacia, Università degli Studi di Parma, Parma 43124, Italy. marco.mor@unipr.it.
Alessio LodolaDipartimento di Farmacia, Università degli Studi di Parma, Parma 43124, Italy. alessio.lodola@unipr.it.
University of Parma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The EphA2 receptor and its ephrin-A1 ligand form a key cell communication system, which has been found overexpressed in many cancer types and involved in tumor growth. Recent medicinal chemistry efforts have identified bile acid derivatives as low micromolar binders of the EphA2 receptor. However, these compounds suffer from poor physicochemical properties, hampering their use in vivo. The identification of compounds able to disrupt the EphA2-ephrin-A1 complex lacking the bile acid scaffold may lead to new pharmacological tools suitable for in vivo studies. To identify the most promising virtual screening (VS) protocol aimed at finding novel EphA2 antagonists, we investigated the ability of both ligand-based and structure-based approaches to retrieve known EphA2 antagonists from libraries of decoys with similar molecular properties. While ligand-based VSs were conducted using UniPR129 and ephrin-A1 ligand as reference structures, structure-based VSs were performed with Glide, using the X-ray structure of the EphA2 receptor/ephrin-A1 complex. A comparison of enrichment factors showed that ligand-based approaches outperformed the structure-based ones, suggesting ligand-based methods using the G-H loop of ephrin-A1 ligand as template as the most promising protocols to search for novel EphA2 antagonists.

Indexed as

Crystallography, X-RayDatabases, PharmaceuticalDrug DiscoveryEphrin-A1Molecular Docking SimulationMolecular StructureProtein Kinase InhibitorsReceptor, EphA2Structure-Activity RelationshipUser-Computer InterfaceEphrin-A1Protein Kinase InhibitorsReceptor, EphA2dockingdrug designEphA2 antagonistpharmacophore searchPPI inhibitorsshape screeningUniPR129virtual screening

Identifiers

PMID26393553
PMCPMC6331951
OpenAlexW2146190559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.